Rick Simpson Oil (RSO) in Cherokee County, Kansas: The Complete Guide by OilWell Cannabis

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker — a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. For residents of Cherokee County, Kansas, who have been let down by conventional medicine, this story resonates deeply. Whether you’re a cancer patient in Columbus told there are no more options, a veteran in Baxter Springs cycling through ineffective prescriptions, or a chronic pain sufferer in Galena whose doctor dismisses cannabis as an option, the universal experience of medical frustration is the same across our Kansas communities.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused. This pattern of pharmaceutical failure and institutional dismissal mirrors what many Cherokee County residents experience daily in our rural healthcare landscape, where specialists are hours away and alternative medicine options remain limited.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study — originally intended to demonstrate harm — became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials. For Cherokee County readers encountering RSO through online forums, patient support groups, or word-of-mouth, understanding this historical context is crucial.

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed.

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

The crusade — spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities, it was foundational — for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy.

Throughout his public career, Simpson’s position remained consistent and uncompromising: he maintained that cannabis oil — particularly high-THC oil made according to his specific method — could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption.

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions.

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice — roughly 10 to 15 milligrams of oil — taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams.

• Weeks 2 through 5: Double the dose approximately every four days. The target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed.

Administration methods

• Primary method — oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it.
• Secondary method — topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days.
• Not recommended as primary — inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method.

Tolerance and the psychoactive effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period.

Post-protocol maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.

Dietary and lifestyle recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials evaluating this specific protocol.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day, translating to approximately 600 to 900 milligrams of delta-9 THC per day — a dose far exceeding anything studied in controlled clinical settings.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder.
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself.

For Cherokee County residents considering any RSO protocol, we strongly recommend consultation with local healthcare providers at Southeast Kansas Medical Center in Cherokee, Freeman Health System in Joplin (just across the state line), or cancer specialists at the University of Kansas Cancer Center before making treatment decisions.

What is traditional Rick Simpson Oil — the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials.

Source material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization — the starting material varied by availability and growing season.

Extraction solvent

Simpson originally used naphtha — a petroleum-based solvent commercially available as lighter fluid. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue.

Extraction process

1. Dry or semi-dry cannabis plant material was placed in a container.
2. The material was covered with solvent and agitated for several minutes.
3. The solvent was poured off through a filter into a separate collection vessel.
4. The process was repeated with fresh solvent.
5. The combined solvent washes were placed in a rice cooker.
6. The solvent was evaporated at relatively low heat.
7. As the solvent evaporated, a thick, dark oil remained.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and physical characteristics

Traditional RSO was an extremely dark — nearly black — thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. The heat converted essentially all THCa into delta-9 THC.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight.

Terpene content

Minimal to none. The combination of solvent extraction and high-heat evaporation meant that traditional RSO was effectively stripped of its terpene content.

Standardization and testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, and the individual maker’s process. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging leaves potentially harmful residues in the finished oil.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, and numerous other conditions.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects but does not endorse cannabis or cannabis oil as a cancer treatment .
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.

For Cherokee County residents facing cancer, this means RSO should be considered as a complementary approach, not a replacement for proven treatments available at regional cancer centers like the University of Kansas Cancer Center or Mercy Hospital Joplin.

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research when most of the world was ignoring it. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients to rely on RSO as a primary treatment in place of proven oncologic therapies carries genuine harm potential.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format.

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas we offer to Cherokee County residents.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not available or performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual solvents	Significant risk with naphtha	Controlled and tested — solvent-free production
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why our formulas diverge from traditional RSO

Our formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids because the entourage-effect literature suggests potential benefit from cannabinoid diversity [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. We include live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible and supported at the preclinical level [20]-[28].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining content across CBD, CBG, CBN, and CBC.

• Product format innovation. Simpson envisioned only one format: an oral oil. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation.

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol — neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging leaves potentially harmful residues.

Our RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

We use organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent converted essentially all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity.

Our sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This creates three distinct usage options:

Option 1 — Raw, no heat. All 1,500 mg stays as THCa — completely non-psychoactive. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2 — Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes converts 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg of delta-9 THC, this yields approximately 1,405 mg of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

Option 3 — Vape, auto-decarboxylation. The vape cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids.

This design puts the potency decision entirely in your hands — aligning with Rick Simpson’s principle that patients should control their own medicine.

Terpene loss in traditional RSO

Traditional RSO was essentially stripped of terpenes by the solvent and heat destruction process. Our formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile discussed below.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework, no standardized testing infrastructure, no legal pathway for clinical research, and no peer-reviewed journals dedicated to cannabis therapeutics.

This document takes a fundamentally different approach. We apply a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain extract. A direct comparison between his dosing and dosing with our modern, standardized, multi-cannabinoid formulation is not straightforward.

Key differences for Cherokee County users:

• Our sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds
• Simpson’s oil was approximately 60 to 90 percent delta-9 THC. Our formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL)
• Our formula includes 1,500 mg of THCa that you can activate at your discretion
• Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. Our entire bottle contains only 90 mg of delta-9 THC

Dosing guidance for our products should be developed independently of Simpson’s protocol, informed by responsible titration principles: start low, go slow.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. While our headquarters are in Houston, our mission to provide accessible, high-quality cannabinoid medicine extends directly to Cherokee County, Kansas. Colin grew up in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico — in one of the most economically challenged and dangerous regions along the border. That experience of resilience in adversity shapes how we approach serving rural communities like Cherokee County, where healthcare access can be just as challenging as it was in the Borderplex.

Colin’s childhood was marked by exposure to both opportunities and dangers. By sixteen, he had to leave home for good after seeing friends killed or imprisoned. Despite these dangers, he chose cannabis over darker paths, seeing it as a safer alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows, then transitioned to creating a legal, legitimate business.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — defines our approach and ensures Cherokee County residents receive products made with pharmaceutical-level care.

Bentley’s story — the foundation of everything

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet — he was family. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?” Colin had cannabis experience — but it was recreational. He had never explored the therapeutic applications.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It was not a cure, but it was hope. And that hope delivered what veterinary medicine said was impossible: Bentley got up. He walked over and brought his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect — dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. This lesson — that complex conditions require complex solutions — is what makes our seven-cannabinoid RSO formula relevant to Cherokee County residents dealing with multiple health challenges.

Colin’s personal journey — PTSD and benzodiazepine addiction

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — a feat that is notoriously difficult and dangerous — using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

For Cherokee County residents struggling with PTSD — whether veterans returning from service, survivors of trauma, or anyone trapped in prescription cycles — this personal experience makes our approach credible in a way no corporate brand can be.

Doctors use our formulas

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

While Kansas has a more restrictive medical cannabis program than Texas, many integrative medicine practitioners across the state recognize the value of evidence-informed cannabinoid formulations. Our open-source philosophy allows these practitioners to understand exactly what they’re recommending to their Cherokee County patients.

ABC13 media recognition — seven features over four years

Between September 2019 and April 2023, ABC13 Houston (KTRK) — the ABC affiliate serving America’s fourth-largest city — featured Colin Valencia and OilWell Cannabis in seven distinct news segments. Five different ABC13 reporters sought us out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter.

For Cherokee County residents, this mainstream media validation from a major-market ABC affiliate establishes credibility that transcends geography. When major media needs to explain cannabis products, legal changes, or community health initiatives, they turn to voices they trust. That trust is what we bring to serving Kansas communities.

Our philosophy in Colin’s own words

From our first ABC13 feature in September 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This principle — honest education over hype — guides every interaction with Cherokee County customers.

Current operations and Kansas access

OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We have been operating since 2019, generate approximately one million dollars in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed.

For Cherokee County residents, while we cannot offer same-day delivery like we do in Houston, we ship directly to Columbus, Baxter Springs, Galena, and every community across the county. Our products are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only our own recipes and ideas.

The OilWell RSO philosophy

Our RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define our approach:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States, including to every address in Cherokee County, Kansas. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; we engineered a product that puts that control in your hands through chemistry.

3. Open-source formulas. We publish our complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents our commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and Kansas legal framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of our RSO product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3% threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and can be shipped to Kansas.

For Cherokee County residents specifically: Kansas maintained its own hemp program following the 2018 Farm Bill. Our products comply with both federal and Kansas state hemp laws. Unlike Kansas’s medical cannabis program, which requires qualifying conditions and physician registration, our Farm Bill-compliant products require only age verification (21+). No medical card needed.

THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC. You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes.

The conversion chemistry: 1,500 mg of THCa converts to approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg of delta-9 THC, this produces approximately 1,405 mg of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with Kansas laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. Kansas law permits possession of hemp-derived products with less than 0.3% delta-9 THC.

Open-source formulas — why we publish everything

We publish our complete RSO formulas — every cannabinoid, every milligram amount, every percentage — in public documents including this one. If you cannot afford our products — $129.99 for the sublingual oil, $49.99 for the vape cartridge — you can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make your own version.

This is a direct echo of Rick Simpson’s original ethos. He gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. We adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

CBD golden paste recipe for pets — the original open-source formula

We published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water in a saucepan over low heat, stirring continuously until it forms a thick paste (7-10 minutes).
2. Add the coconut oil and pepper and stir until thoroughly mixed.
3. Cool and store in a jar with a lid in the refrigerator for up to two weeks.
4. Add CBD oil before giving to your pet, adjusting dosage based on weight and needs.

This recipe — published for free, years before the RSO formulas were open-sourced — demonstrates that the pattern is consistent. We gave away the formula that saved Bentley before we gave away the formula designed for people.

The decarboxylation choice — patient-controlled potency

Traditional RSO was always fully decarboxylated, leaving the patient with no choice about psychoactivity. Our sublingual formula contains 1,500 mg of THCa in its acidic, non-psychoactive form, creating three distinct usage options:

Option 1 — Raw, no heat. All 1,500 mg stays as THCa — completely non-psychoactive. Compatible with work, driving, and daytime use with zero impairment.

Option 2 — Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes converts THCa to delta-9 THC, yielding approximately 1,405 mg of total delta-9 THC. This gives the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion.

Option 3 — Vape, auto-decarboxylation. The vape cartridge vaporizes at 400 to 450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids.

This design puts the potency decision entirely in your hands — aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry.

Solvent-free production

Our RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present.

We use organic MCT oil as the carrier base. Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request.

The broader OilWell product portfolio

Beyond RSO, we produce:

Asshole Peach — Our most popular product, particularly favored by veterans for PTSD and pain relief.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction.

Custom creations — We offer custom-made products tailored to specific needs, including formulations for vegans, diabetics, and those with unique health circumstances.

Two product formats for Cherokee County residents

We offer the RSO formula in two delivery formats:

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Approximately 40-60 doses per bottle

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900+ mg total cannabinoids
• Same six-cannabinoid ratio (no separate delta-9 THC listing)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest delivery)
• Duration: 2-4 hours
• Automatic THCa decarboxylation at vaping temperature

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive comparison for Cherokee County shoppers

OilWell RSO vs. Kansas medical cannabis (TCUP)

Dimension	Kansas medical cannabis	OilWell RSO
Cannabinoid profile	THC-only	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated
Access requirements	Kansas medical card with qualifying condition	Age 21+ only, no medical card required
Delivery	Must travel to licensed dispensary (nearest in Wichita or Kansas City)	Ships directly to Cherokee County homes
Farm Bill compliant	No — state medical program	Yes — less than 0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Typical hemp RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	Minimal	3,000 mg
CBN content	Minimal	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible)	Minimal	1,500 mg
Psychoactive option	No	Yes — via THCa decarboxylation

Condition-specific usage context for Cherokee County residents

Important disclaimer: The following contexts are informed by cannabinoid research but are not medical prescriptions. These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0 mL sublingual ~1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)

Chronic pain (arthritis, neuropathy, fibromyalgia)

• Daytime: 0.3-0.5 mL raw sublingual — anti-inflammatory without psychoactive impairment, perfect for Cherokee County residents who work in agriculture, manufacturing, or need to stay functional
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Sleep support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, delivers 50 mg CBN — the dosage level investigated in 2024 sleep literature
• Particularly relevant for Cherokee County residents whose sleep is disrupted by chronic pain or PTSD

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety without impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture

General titration principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, and concurrent medications.

Delivery and global accessibility for Cherokee County

While we cannot offer same-day delivery to Cherokee County like we do in Houston, we ship directly to every Kansas address via USPS Priority Mail (2-3 business days), FedEx, or UPS Ground (3-5 business days).

Shipping to Cherokee County:

• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available
• All packages include full documentation and Certificates of Analysis

International shipping: We ship internationally and have delivered to multiple countries. The THCa legal framework makes this possible: because the product contains less than 0.3% delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill. International customers accept all customs and legal responsibility.

For Cherokee County residents, this means access to clinical-strength multi-cannabinoid RSO without needing to drive hours to a licensed dispensary in Wichita or Kansas City. The product comes to your door, legally, with full documentation.

How our formulas connect to the evidence

Every cannabinoid in our formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in the GENERAL KNOWLEDGE section below. Every terpene — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — is covered with preclinical and review-level evidence.

The formulas are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging, and what is overstated. We do not exempt ourselves from the same evidence standards we apply to the broader field.

OilWell Cannabis is more than a brand — it is a promise to Cherokee County customers that we will always strive to deliver the best, most thoughtful cannabis products available. As we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that has defined us from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia — Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought us out across those years. This media record establishes the credibility we bring to serving Cherokee County residents.

Feature: Texas CBD businesses booming — September 15, 2019

Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Feature: Entrepreneur creates direct-to-consumer business — March 22, 2021

Colin’s therapy quote: “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

Feature: What is Delta 8 THC — May 24, 2021

Steve Campion’s exchange with Colin:

• Campion: “Why would someone want to smoke that?”
• Colin: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

Feature: Houston CBD shop giving away free products for COVID vaccine — August 20, 2021

We gave away 1,000 special edition caviar pre-rolls (approximately $35,000 in product) to encourage COVID vaccination. We coordinated with the city of Houston, with no political strings attached.

Feature: Texas ban over Delta 8 — October 19, 2021

When Texas reclassified Delta-8 as Schedule I overnight, Colin proactively removed all Delta-8 products before enforcement began and warned other operators who were unknowingly shipping Schedule I narcotics.

Feature: Biden marijuana pardon — October 7, 2022

This feature revealed Colin’s personal marijuana conviction history: “You face challenges with housing, loans, and banking, I mean with about everything.” and “I would love to see people not get hurt for this anymore.”

Feature: Marijuana industry getting creative — April 21, 2023

Colin’s Renaissance framing: “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

Complete index of Colin’s quotes

All 13 quotes are preserved in the directive document. Each demonstrates consistency, honesty, and personal stakes over four years.

The through-line

These seven features reveal five themes: consistency across years, breadth of expertise, community action ($35K vaccine giveaway, Delta-8 proactive removal), personal stakes (conviction history), and evolution of language. This recognition cannot be purchased — it can only be earned.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters here because the evidence base is not evenly distributed. Of the compounds listed in this document, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS [1].
• NCCIH also emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns repeatedly highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, contamination, and labeling inaccuracy [1].

Cannabinoids

CBD

• Strongest human evidence in seizure disorders [1][2].
• 2024 systematic review found statistically significant anxiolytic signal but stressed limited clinical sample [3].
• 2024 pain review concluded promising but heterogeneous evidence [4].
• 2023 sleep review found methodologically weak literature [5].
• 2023 safety review found real signal for liver enzyme elevation [6].

CBG

• Mostly review-level and preclinical; human evidence remains sparse [7][8].
• 2021 pharmacology review notes CBG is being sold commercially while evidence base remains thin [7].

Delta-8 THC

• Pharmacologically relevant and psychoactive, much less clinically characterized than delta-9 THC [9]-[11].
• 2023 scoping review found evidence base dominated by animal studies and public-health concerns [10].

THCa

• Important chemically but low on direct human therapeutic evidence [12].
• Does not produce psychoactive effects unless decarboxylated [12].

Delta-9 THC

• Strongest human evidence of psychoactive cannabinoids [1][13]-[15].
• 2022 pain review found short-term benefit but increased adverse events [13].
• 2025 review found unfavorable associations with psychosis and cannabis use disorder [15].

CBN

• Weak human evidence; marketing ahead of data [16][17].
• 2021 sleep review found no clinical trials using validated measures [16].

CBC

• Emerging, intriguing, overwhelmingly preclinical [18][19].
• 2024 review notes products being sold despite little clinical efficacy evidence [18].

Terpenes

Terpene claims need stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene — Multifunctional monoterpene with antioxidant, anti-inflammatory properties, but mostly nonhuman literature [21][22].

Myrcene — Anxiolytic, anti-inflammatory properties described, but human studies lacking [23].

Caryophyllene — Selective CB2 receptor agonist, most mechanistically interesting terpene, but human clinical confirmation limited [24].

Pinene — Antioxidant, anti-inflammatory, neuroprotective signals, but well-designed clinical trials lacking [25].

Linalool — Stress and mood pharmacology discussed, but human trials limited [22][25][26].

Humulene — Anti-inflammatory biologic effects shown, but human efficacy not established [27].

Terpinolene — Range of reported biological effects, but evidence dominated by preclinical studies [28].

Research limits and interpretation

• Evidence base is highly uneven [1]-[29].
• Extract/molecule/synthetic/terpene data are not interchangeable.
• Minor cannabinoids are commercially interesting because underexplored, but claims often inflated.
• Product quality matters as much as molecule identity [1][10][11][14].
• For THCa, chemistry changes with storage/heating [12].

Common overstatements to avoid

• CBN as proven sleep aid → Evidence remains weak [16][17].
• Myrcene as proven sedative → Human proof limited [23].
• Terpenes have proven entourage effects → Clinical proof limited [20][29].
• THCa is always nonpsychoactive → Heating converts it to THC [12].
• Delta-8 is safe because hemp-derived → Psychoactive with incomplete safety data [9]-[11].

Practical takeaways for our formulas

• CBD and delta-9 THC most evidence-developed.
• Delta-8 THC is not trivial; psychoactive with less robust characterization.
• THCa changes meaningfully with processing.
• CBG, CBN, CBC scientifically credible but clinically immature.
• Terpene claims should be careful and conservative.

References

[1] National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH.

[2] Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy. Exp Neurol. 2023;359:114238.

[3] Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders. Psychiatry Res. 2024;339:116049.

[4] Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in pain treatment. Pharmaceuticals Basel. 2024;17(11):1438.

[5] Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in insomnia management. Cannabis Cannabinoid Res. 2023;8(2):213-229.

[6] Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity. J Intern Med. 2023;293(6):724-752.

[7] Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.

[8] Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review. Molecules. 2024;29(22):5471.

[9] Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC. Br J Pharmacol. 2022;179(15):3915-3933.

[10] LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review. Addiction. 2023;118(6):1011-1028.

[11] Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.

[12] Moreno-Sanz G. Can You Pass the Acid Test? Cannabis Cannabinoid Res. 2016;1(1):124-130.

[13] McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain. Ann Intern Med. 2022;175(8):1143-1153.

[14] Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.

[15] Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol products and mental health. Ann Intern Med. 2025;178(10):1429-1440.

[16] Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.

[17] Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep. Curr Psychiatry Rep. 2024;26(12):712-727.

[18] Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene. J Pharmacol Exp Ther. 2024;391(2):206-213.

[19] Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene. Acta Pharm. 2021;71(3):355-364.

[20] André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect. Pharmaceuticals Basel. 2024;17(11):1543.

[21] Anandakumar P, Kamaraj S, Vanitha MK. D-limonene. J Food Biochem. 2021;45(1):e13566.

[22] Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides. Contact Dermatitis. 2022;87(1):1-12.

[23] Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene. Front Nutr. 2021;8:699666.

[24] Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. Beta-caryophyllene. Biomed Pharmacother. 2021;140:111639.

[25] Weston-Green K, Clunas H, Jimenez Naranjo C. Pinene and linalool. Front Psychiatry. 2021;12:583211.

[26] Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool and depression. Curr Neuropharmacol. 2022;20(6):1073-1092.

[27] Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. Alpha-humulene. Planta Med. 2024;90(9):664-674.

[28] Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Terpinolene. Phytomedicine. 2021;93:153768.

[29] Russo EB. Taming THC. Br J Pharmacol. 2011;163(7):1344-1364.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Carrier: Organic MCT oil
• Price: $129.99

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%
Live Terpenes	5%+
Format	1 Gram cartridge

• Battery: 510-thread universal compatibility
• Price: $49.99

TERPENE PROFILE (Both Products)

• Limonene — citrus-bright, mood-enhancing
• Myrcene — earthy, relaxing
• Caryophyllene (β-caryophyllene) — pepper/spice, CB2 agonist
• Pinene — forest-fresh, clarity
• Linalool — floral, lavender, calming
• Humulene — earthy, woody, anti-inflammatory
• Terpinolene — piney, fruity, complex

To order for delivery to Cherokee County, Kansas: Visit oilwellcbd.com or call (832) 416-2816. All orders ship with complete documentation, third-party lab results, and our commitment to honest education. Age 21+ only. Please consult your healthcare provider before use. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.